Once-a-month HIV treatment sees promising phase III resultsJanssen and ViiV have reported positive data for their once-monthly injectable HIV combo regimen in two phase III Share XOnce-a-month HIV treatment sees promising phase III resultshttps://pharmaphorum.com/news/once-a-month-hiv-treatment-sees-promising-phase-iii-results/
Johnson & Johnson: Partnering to eliminate diseaseJ&J’s global head of external innovation communication on how partnerships are fuelling the company’s vision for a World Share XJohnson & Johnson: Partnering to eliminate diseasehttps://pharmaphorum.com/views-and-analysis/johnson-johnson-partnering-to-eliminate-disease/
J&J pays $3.4 billion for robotics firm AurisJohnson & Johnson’s rumoured interest in Auris Health has been confirmed with a $3.3 billion buyout deal that Share XJ&J pays $3.4 billion for robotics firm Aurishttps://pharmaphorum.com/news/jj-pays-robotics-firm-auris/
FDA panel backs J&J’s potential depression blockbusterA panel of advisers to the FDA has voted in favour of approving Johnson & Johnson’s experimental nasal Share XFDA panel backs J&J’s potential depression blockbusterhttps://pharmaphorum.com/news/fda-panel-backs-jjs-potential-depression-blockbuster/
R&D roundup – Sage impresses at JP MorganOne of the biggest headline-grabbers at the 2019 JP Morgan Healthcare conference this week was Sage Therapeutics unveiling Share XR&D roundup – Sage impresses at JP Morganhttps://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-sage-impresses-at-jp-morgan/
J&J hits back over asbestos in talc claimsShares in Johnson & Johnson slid around 10% on Friday after a Reuters article claimed the company had Share XJ&J hits back over asbestos in talc claimshttps://pharmaphorum.com/news/jj-hits-back-over-asbestos-in-talc-claims/
FDA clears cardiovascular claim for J&J’s InvokanaJohnson & Johnson finally has some good news to report for its diabetes blockbuster Invokana, after the FDA Share XFDA clears cardiovascular claim for J&J’s Invokanahttps://pharmaphorum.com/news/fda-clears-cardiovascular-claim-for-jjs-invokana/
J&J preps for FDA panel grilling over depression drugJohnson & Johnson is “confident” about regulatory reviews of its depression drug esketamine ahead of a likely grilling Share XJ&J preps for FDA panel grilling over depression drughttps://pharmaphorum.com/news/janssen-preps-for-fda-panel-grilling-esketamine/
New data sets up potential new gastro use for J&J’s StelaraJanssen’s Stelara has shown positive results in an ulcerative colitis (UC) trial, setting up a potential new indication Share XNew data sets up potential new gastro use for J&J’s Stelarahttps://pharmaphorum.com/news/new-data-sets-up-potential-new-gastro-use-for-jjs-stelara/
